11/19
01:30 pm
algs
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
High
Report
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
11/7
08:36 am
algs
Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
High
Report
Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
11/6
07:28 pm
algs
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
High
Report
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/6
04:05 pm
algs
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Medium
Report
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
10/30
04:05 pm
algs
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
Low
Report
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
10/23
08:18 am
algs
Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
10/22
09:04 am
algs
Aligos Therapeutics up on FDA clearance of IND application for its Hepatitis B treatment [Seeking Alpha]
Medium
Report
Aligos Therapeutics up on FDA clearance of IND application for its Hepatitis B treatment [Seeking Alpha]
10/22
08:00 am
algs
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
Medium
Report
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
10/15
09:00 am
algs
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
Low
Report
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
10/11
08:00 am
algs
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/1
08:00 am
algs
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
Low
Report
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
9/30
08:00 am
algs
Aligos Therapeutics to Present at Investor Conferences in October
Medium
Report
Aligos Therapeutics to Present at Investor Conferences in October
9/24
08:00 am
algs
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
Low
Report
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
9/20
08:12 am
algs
Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
High
Report
Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
9/20
05:28 am
algs
Aligos reports positive data from Phase IIa MASH treatment trial [Yahoo! Finance]
High
Report
Aligos reports positive data from Phase IIa MASH treatment trial [Yahoo! Finance]
9/19
08:00 am
algs
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
High
Report
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
9/18
05:00 pm
algs
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
High
Report
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
9/13
08:00 am
algs
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/10
11:22 am
algs
Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year? [Yahoo! Finance]
Medium
Report
Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year? [Yahoo! Finance]
8/22
06:25 pm
algs
Three High Growth Tech Stocks in China to Watch [Yahoo! Finance]
Medium
Report
Three High Growth Tech Stocks in China to Watch [Yahoo! Finance]